Emma Reeve - Oct 30, 2025 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
Director
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Stock symbol
PTCT
Transactions as of
Oct 30, 2025
Transactions value $
-$631,587
Form type
4
Date filed
10/31/2025, 05:20 PM
Previous filing
Oct 7, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Reeve Emma Director C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN /s/ Avraham S. Adler, Attorney-in-Fact 2025-10-31 0001680329

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Sale -$255K -3.67K -35.48% $69.50 6.67K Oct 30, 2025 Direct F1
transaction PTCT Common Stock Options Exercise $457K +12K +180.02% $38.10 18.7K Oct 30, 2025 Direct F1
transaction PTCT Common Stock Sale -$834K -12K -64.29% $69.50 6.67K Oct 30, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Options Exercise $0 -12K -100% $0.00 0 Oct 30, 2025 Common Stock 12K $38.10 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025.
F2 Currently exercisable.